Key result
Aficamten improves exercise capacity by ~1.7 mL/kg/min vs. placebo in symptomatic obstructive HCM.
Why the study?
This article summarises the developmental milestones leading to the first approvals of aficamten for symptomatic obstructive hypertrophic cardiomyopathy.
Does aficamten improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy?
RCT (n=282)
Double-blind
1:1
Yes
Does aficamten improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy?
Aficamten has received its first global approvals for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May support aficamten use in symptomatic obstructive HCM; leaves open long-term outcomes and comparative data.
Aficamten (MYQORZO™) is a small-molecule cardiac myosin inhibitor being developed by Cytokinetics for the treatment of hypertrophic cardiomyopathy (HCM). Supported by the findings of the phase III, randomised, double-blind, placebo-controlled SEQUOIA-HCM trial, in December 2025 aficamten was approved in both China and the USA to improve functional capacity and symptoms in adults with symptomatic obstructive HCM (oHCM). Subsequently, in February 2026, aficamten was also approved in the EU for the treatment of symptomatic oHCM in adult patients. Aficamten is also in phase III evaluation for use in the treatment of non-obstructive HCM (nHCM) in adults. This article summarises the milestones in the development of aficamten leading to this first approval for symptomatic oHCM.
No takes yet. Share an insight, caveat, or question.
Matt Shirley (2026) conducted an RCT in Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) (n=282). Aficamten vs. Placebo was evaluated on Change from baseline in peak oxygen uptake (pVO2) by CPET at Week 24 (Mean difference 1.7, 95% CI 1.0, 2.4, p=<0.0001).
Synapse has enriched 10 related papers. Consider them for comparative context: